From WikiProjectMed
Jump to navigation Jump to search

Combination of
RifampicinRifamycin antibiotic
IsoniazidAnti-tuberculosis medication
PyrazinamideAnti-tuberculosis medication
Trade namesRifater, Trifazid, others
Clinical data
  • C
Routes of
By mouth
Defined daily dosenot established[1]
External links
AHFS/Drugs.comFDA Professional Drug Information
License data
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)

Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, is a medication used to treat tuberculosis.[2] It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide.[2] It is used either by itself or along with other antituberculosis medication.[2] It is taken by mouth.[2]

Side effects are those of the underlying medications.[2] These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness.[3] Severe side effects include liver problems.[4] Use in those under the age of 15 may not be appropriate.[4] It is unclear if use in pregnancy is safe for the baby.[4]

Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994.[4] It is on the World Health Organization's List of Essential Medicines.[5] The wholesale cost in the developing world is about US$3.93 a month.[6] In the United Kingdom a month of treatment costs the NHS about 39.51 pounds.[7]

Medical uses

The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications.[8] Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.


The defined daily dose is not established.[1]

Society and culture

It is manufactured by Aventis.[citation needed]

See also


  1. 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 18 September 2020. CS1 maint: discouraged parameter (link)
  2. 2.0 2.1 2.2 2.3 2.4 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 143. hdl:10665/44053. ISBN 9789241547659.
  3. "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016. CS1 maint: discouraged parameter (link)
  4. 4.0 4.1 4.2 4.3 "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016. CS1 maint: discouraged parameter (link)
  5. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. "Rifampicin + Isoniazid + Pyrazinamide". International Drug Price Indicator Guide. Retrieved 8 December 2016. CS1 maint: discouraged parameter (link)
  7. British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 403. ISBN 9780857111562.
  8. Brown, Morris J.; Sharma, Pankaj; Bennett, Peter N. (30 July 2012). Clinical Pharmacology. Elsevier Health Sciences. p. 204. ISBN 978-0-7020-5113-5.

External links